Cidara Therapeutics, Inc. - Common Stock (CDTX)

One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks.

Here are the top movers in Friday's session, showcasing the stocks with significant price changes.

Intrigued by the market activity in the middle of the day on Friday? Uncover the key winners and losers of today's session in our insightful analysis.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.

The company is getting deeper into the antiviral space, buying a company working on a long-acting drug to protect against flu.

Merck (NYSE: MRK) to acquire Cidara (NASDAQ: CDTX) for $9.2 billion, diversifying its portfolio with CD388.

Discover the top movers in Friday's pre-market session and stay informed about market dynamics.

With the new deal, Merck would gain access to CD388, currently in late-stage development, and designed to prevent influenza infection in individuals at higher risk of influenza complications.

Cidara Therapeutics shares jumped over 42% in after-hours trading following a 13D filing and Phase 3 enrollment milestone.

JP Morgan initiated coverage on Cidara Therapeutics with Overweight rating & tgt of $200, citing lead flu asset CD388's game-changing potential.

Cidara Therapeutics Inc (NASDAQ:CDTX) shares are trading higher on Friday after the biotech company made a recent announcement about their presentation at the upcoming ESWI 2025 conference. JP Morgan also began coverage of the stock, assigning it an Overweight rating and setting a price target of $200.

The company earned an important fast-track review designation for a pipeline medication.

Cidara shares are trading higher Friday after the company secured $339 million in BARDA funding to advance its CD388 pandemic influenza therapeutic and onshore its manufacturing.